How deep is the relationship between LABS & traditional global pharma partner? Well let me put it mathematically so it is concise, clear, and logical. The CEO of LABS stated they are basically 'debt free' and own their 'assets outright'. The CEO also stated we have "over 20 strong clinical trials, many in late stage". Well that doesn't come cheap by any means because the average cost of clinical trial, based on compiled U.S. data, ranges from $4.6 million CAD up to $25.8 million CAD.
Let's take the very low end of the scale folks at $4.6 million CAD per clinical trial and bang that at over 20 strong clinical trials many in late stage, so since it is 'over' 20, let us be very conservative at 21. 21 clincial trials now many in late stage would put Medipharm Labs very easily in DEBT on their BALANCE SHEET at OVER $80 million CAD.
That's a deep relationship and because LABS is in Canada handling cannbinoid based molecules, a U.S. Corporation is subject to Federal Law, as in DEA schedule 1 drug.
Does anybody want to see the peek a boo again, Pfizer Canada, Kirkland Quebec.
Box those numbers in and tell me where LABS funded over $80 million in clinical trials and is still DEBT FREE.
That's a balls deep relationship, what a honeymoon!!!